PedAM
Pediatric Disease Annotations & Medicines
| Disease | c syndrome |
| Phenotype | C0376358|prostate cancer |
| Sentences | 14 |
| PubMedID- 24191227 | Paraneoplastic syndrome associated with prostate cancer is extremely rare. |
| PubMedID- 24368236 | Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. |
| PubMedID- 23060995 | prostate cancer in patients with metabolic syndrome is associated with low grade gleason score when diagnosed on biopsy. |
| PubMedID- 21139643 | The literature features around 100 cases of paraneoplastic syndromes associated with prostate cancer and these include endocrine manifestations, neurological entities, dermatological conditions, and other syndromes. |
| PubMedID- 26275075 | Metabolic syndrome components are associated with increased prostate cancer risk. |
| PubMedID- 25755679 | Higher ages and lower high-density lipoprotein-cholesterol were two parameters that were significant only in the prostate cancer group with metabolic syndrome. |
| PubMedID- 24360772 | Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. |
| PubMedID- 24935591 | The metabolic syndrome is associated with more aggressive prostate cancer. |
| PubMedID- 22096652 | Recent findings from our own group suggest in fact that race modifies the association; metabolic syndrome was positively associated with prostate cancer risk among african american men, but not among caucasian men [13]. |
| PubMedID- 20652272 | Chronic monoarthritis and foot-drop as a paraneoplastic syndrome in prostate cancer. |
| PubMedID- 24552491 | Therefore, several mechanisms could explain the association of obesity and metabolic syndrome with prostate cancer pathogenesis, including sex steroid hormone, insulin and insulin-like growth factors and inflammation pathways [6,57-59]. |
| PubMedID- 20592666 | Docetaxel-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome-related complex in a patient with metastatic prostate cancer. |
| PubMedID- 25541340 | Purpose: androgen deprivation therapy may promote the development of the metabolic syndrome in patients with prostate cancer. |
| PubMedID- 20702155 | The present findings also seem to confirm that prostate cancer is a component of the metabolic syndrome. |
Page: 1